2024-12-06 13:47:18
Latest Post
SIDBI Opens New Branch in Karnal to Boost MSME Growth in Haryana
GPT Healthcare Limited enters into MOU for new hospital at Jamshedpur
RITES Ltd appointed as PMC by IIM Raipur
Globus Spirits Unveils TERAI India Craft Gin - Litchi & Mulberries: A celebration of Heritage and Innovation
Lava cast successfully ships export of Flywheels and Covers to the USA market
Stock Report
Mankind Pharma Ltd's consolidated profit for Q2 FY25 climbs to Rs. 653.47 crores
Posted On : 2024-11-05 17:04:17( TIMEZONE : IST )
Mankind Pharma Limited has reported Consolidated financial results for the period ended September 30, 2024.
Financial Results (Q2 FY2025) - QoQ Comparison
The company has reported total income of Rs. 3185.94 crores during the period ended September 30, 2024 as compared to Rs. 2994.02 crores during the period ended June 30, 2024.
The company has posted net profit / (loss) of Rs. 653.47 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs. 536.49 crores for the period ended June 30, 2024.
The company has reported EPS of Rs. 16.28 for the period ended September 30, 2024 as compared to Rs. 13.37 for the period ended June 30, 2024.
| Financials | Q2 FY2025 | Q1 FY2025 | % Change |
| Total Income | ₹ 3185.94 crs | ₹2994.02 crs |  6.41% |
| Net Profit | ₹653.47 crs | ₹536.49 crs | 21.80% |
| EPS | ₹16.28 | ₹13.37 | 21.77% |
Financial Results (Q2 FY2025) - YoY Comparison
The company has reported total income of Rs. 3185.94 crores during the period ended September 30, 2024 as compared to Rs.2768.08 crores during the period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.653.47 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs.501.03 crores for the period ended September 30, 2023.
The company has reported EPS of Rs.16.28 for the period ended September 30, 2024 as compared to Rs.12.49 for the period ended September 30, 2023.
| Financials | Q2 FY2025 | Q2 FY2024 | % Change |
| Total Income | ₹ 3185.94 crs | ₹2768.08 crs | 15.10% |
| Net Profit | ₹653.47 crs | ₹501.03 crs | 30.43% |
| EPS | ₹16.28 | ₹12.49 | 30.34% |
Financial Results (Half Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.6179.96 crores during the 6 Months period ended September 30, 2024 as compared to Rs.5405.32 crores during the 6 Months period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.1189.96 crores for the 6 Months period ended September 30, 2024 as against net profit / (loss) of Rs.987.90 crores for the 6 Months period ended September 30, 2023.
The company has reported EPS of Rs.29.65 for the 6 Months period ended September 30, 2024 as compared to Rs.24.63 for the 6 Months period ended September 30, 2023.
| Financials | Half Year Ended FY2025 | Half Year Ended FY2024 | % Change |
| Total Income | ₹6179.96 crs | ₹5405.32 crs | 14.33% |
| Net Profit | ₹1189.96 crs | ₹987.90 crs | 20.45% |
| EPS | ₹29.65 | ₹24.63 | 20.38% |
Shares of Mankind Pharma Limited was last trading in BSE at Rs. 2734.95 as compared to the previous close of Rs. 2690.55. The total number of shares traded during the day was 19231 in over 2889 trades.
The stock hit an intraday high of Rs. 2751.00 and intraday low of 2666.40. The net turnover during the day was Rs. 51993508.00.
